Olema Pharmaceuticals (OLMA) Competitors

$13.82 +0.24 (+1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$14.06 +0.23 (+1.70%)

As of 05:41 PM Eastern

OLMA vs. CRSP, DNTH, INDV, NNNN, and CRNX

Should you buy Olema Pharmaceuticals stock or one of its competitors? MarketBeat compares Olema Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Olema Pharmaceuticals include CRISPR Therapeutics (CRSP), Dianthus Therapeutics (DNTH), Indivior (INDV), Anbio Biotechnology (NNNN), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.

How does Olema Pharmaceuticals compare to CRISPR Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Olema Pharmaceuticals has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-49.15%	-43.86%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Olema Pharmaceuticals has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$1.86	N/A
CRISPR Therapeutics	$1M	4,865.85	-$581.60M	-$6.22	N/A

Olema Pharmaceuticals has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 14 mentions for Olema Pharmaceuticals and 10 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.79 beat Olema Pharmaceuticals' score of 0.38 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 219.10%. CRISPR Therapeutics has a consensus price target of $65.47, indicating a potential upside of 29.77%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Olema Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Olema Pharmaceuticals beats CRISPR Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Dianthus Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	3,491.91	-$162.34M	-$4.13	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$1.86	N/A

Olema Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Olema Pharmaceuticals	N/A	-49.15%	-43.86%

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 17 mentions for Dianthus Therapeutics and 14 mentions for Olema Pharmaceuticals. Dianthus Therapeutics' average media sentiment score of 1.12 beat Olema Pharmaceuticals' score of 0.38 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dianthus Therapeutics currently has a consensus price target of $117.82, suggesting a potential upside of 38.06%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 219.10%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Dianthus Therapeutics beats Olema Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Indivior?

Indivior (NASDAQ:INDV) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Indivior has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.72	$210M	$1.95	19.40
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$1.86	N/A

Indivior currently has a consensus price target of $39.33, suggesting a potential upside of 3.97%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 219.10%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

60.3% of Indivior shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Indivior has a net margin of 19.44% compared to Olema Pharmaceuticals' net margin of 0.00%. Olema Pharmaceuticals' return on equity of -49.15% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Olema Pharmaceuticals	N/A	-49.15%	-43.86%

Indivior has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 7 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Olema Pharmaceuticals and 7 mentions for Indivior. Indivior's average media sentiment score of 1.56 beat Olema Pharmaceuticals' score of 0.38 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Olema Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Indivior beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Anbio Biotechnology?

Olema Pharmaceuticals (NASDAQ:OLMA) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Anbio Biotechnology has higher revenue and earnings than Olema Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$1.86	N/A
Anbio Biotechnology	$8.65M	417.19	$6.40M	N/A	N/A

Olema Pharmaceuticals currently has a consensus price target of $44.10, suggesting a potential upside of 219.10%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Olema Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anbio Biotechnology's return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-49.15%	-43.86%
Anbio Biotechnology	N/A	N/A	N/A

Olema Pharmaceuticals has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its share price is 371% more volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 13 more articles in the media than Anbio Biotechnology. MarketBeat recorded 14 mentions for Olema Pharmaceuticals and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.19 beat Olema Pharmaceuticals' score of 0.38 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Olema Pharmaceuticals	Neutral
Anbio Biotechnology	Positive

Summary

Olema Pharmaceuticals and Anbio Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Crinetics Pharmaceuticals presently has a consensus price target of $76.13, suggesting a potential upside of 98.71%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 219.10%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Olema Pharmaceuticals has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Olema Pharmaceuticals	N/A	-49.15%	-43.86%

In the previous week, Crinetics Pharmaceuticals had 19 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 33 mentions for Crinetics Pharmaceuticals and 14 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.38 beat Crinetics Pharmaceuticals' score of -0.04 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Olema Pharmaceuticals has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$18.07M	223.55	-$465.32M	-$5.13	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$1.86	N/A

Crinetics Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

Summary

Olema Pharmaceuticals beats Crinetics Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.21B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-6.84	18.81	20.87	25.58
Price / Sales	N/A	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	2.35	6.74	9.86	6.70
Net Income	-$162.45M	$24.11M	$3.55B	$333.77M
7 Day Performance	-8.66%	0.07%	-0.32%	0.45%
1 Month Performance	-15.21%	0.84%	1.34%	4.06%
1 Year Performance	207.11%	78.10%	41.03%	36.21%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	2.2834 of 5 stars	$13.82 +1.8%	$44.10 +219.1%	+190.2%	$1.21B	N/A	N/A	70	Earnings Report Analyst Forecast Analyst Revision
CRSP CRISPR Therapeutics	3.41 of 5 stars	$51.96 -3.0%	$64.53 +24.2%	+41.7%	$5.01B	N/A	N/A	460	Analyst Forecast
DNTH Dianthus Therapeutics	3.083 of 5 stars	$89.17 -0.2%	$115.55 +29.6%	+355.1%	$4.87B	$2.04M	N/A	80	Positive News
INDV Indivior	3.7624 of 5 stars	$39.35 +0.9%	$39.33 0.0%	+242.7%	$4.79B	$1.24B	20.16	1,051	Positive News
NNNN Anbio Biotechnology	0.8945 of 5 stars	$31.45 +4.9%	N/A	N/A	$4.53B	$8.65M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. CRSP, DNTH, INDV, NNNN, and CRNX

How does Olema Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Dianthus Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Indivior?

Summary

How does Olema Pharmaceuticals compare to Anbio Biotechnology?

Summary

How does Olema Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. CRSP, DNTH, INDV, NNNN, and CRNX

How does Olema Pharmaceuticals compare to CRISPR Therapeutics?

Do institutionals and insiders have more ownership in OLMA or CRSP?

Is OLMA or CRSP more profitable?

Which has higher earnings and valuation, OLMA or CRSP?

Which has more volatility and risk, OLMA or CRSP?

Does the media prefer OLMA or CRSP?

Do analysts recommend OLMA or CRSP?

Summary

How does Olema Pharmaceuticals compare to Dianthus Therapeutics?

Which has preferable valuation & earnings, DNTH or OLMA?

Is DNTH or OLMA more profitable?

Does the media refer more to DNTH or OLMA?

Which has more risk and volatility, DNTH or OLMA?

Do institutionals & insiders hold more shares of DNTH or OLMA?

Do analysts rate DNTH or OLMA?

Summary

How does Olema Pharmaceuticals compare to Indivior?

Which has preferable valuation & earnings, INDV or OLMA?

Do analysts rate INDV or OLMA?

Do institutionals & insiders hold more shares of INDV or OLMA?

Is INDV or OLMA more profitable?

Which has more risk and volatility, INDV or OLMA?

Does the media refer more to INDV or OLMA?

Summary

How does Olema Pharmaceuticals compare to Anbio Biotechnology?

Which has higher earnings & valuation, OLMA or NNNN?

Do analysts rate OLMA or NNNN?

Do insiders and institutionals hold more shares of OLMA or NNNN?

Is OLMA or NNNN more profitable?

Which has more volatility & risk, OLMA or NNNN?

Does the media refer more to OLMA or NNNN?

Summary

How does Olema Pharmaceuticals compare to Crinetics Pharmaceuticals?

Do analysts prefer CRNX or OLMA?

Is CRNX or OLMA more profitable?

Does the media prefer CRNX or OLMA?

Do institutionals and insiders hold more shares of CRNX or OLMA?

Which has better earnings & valuation, CRNX or OLMA?

Which has more volatility & risk, CRNX or OLMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools